Regulatory
FDA Approves First RAS-Targeted Drug for Pancreatic Cancer, Nearly Doubling Survival in Trial
Revolution Medicines’ Rasonque (daraxonrasib) is the first targeted therapy to hit RAS — the mutation driving over 90% of pancreatic cancers — extending median survival to 13.2 months versus 6.7 on chemo.